Génomic Vision SA EBITDA margin
Cos'è EBITDA margin di Génomic Vision SA?
EBITDA margin di Génomic Vision SA è -342.13%
Qual è la definizione di EBITDA margin?
EBITDA margin is a profitability ratio that measures how much EBITDA the company generates as a percentage of revenue.
ttm (trailing twelve months)
EBITDA margin measures how much of EBITDA is generated as a percentage of sales. It measures the company’s operating profit as a percentage of its revenue and is calculated as EBITDA (earnings before interest, taxes, depreciation, and amortization) divided by total revenue.
EBITDA margin also helps with judging the effectiveness of cost-cutting processes at the company. The higher the company’s EBITDA margin, the lower operating expenses are in respect to revenue. As a result, a higher EBITDA margin is considered more favorable. Smaller companies can have higher EBITDA margins since they are able to operate more efficiently and maximize their profitability.
EBITDA excludes interest on debt, taxes, and capital expenditures, the margin does not provide a perfectly clear estimate of the business’s cash flow generation. Furthermore, EBITDA margin is not recognized as a GAAP (generally accepted accounting principles) metric.
EBITDA margin di aziende nel Health Care settore su EURONEXT rispetto a Génomic Vision SA
Cosa fa Génomic Vision SA?
Genomic Vision Société Anonyme, a molecular diagnostics and technology company, engages in the development of single DNA detection tools for research and in vitro diagnostics in France. The company offers FiberVision, a molecular combing platform that helps in DNA analysis workflow; FiberComb, a molecular combing system, which stretches single DNA molecules onto a vinyl silane glass surface; FiberVision, a scanner that acquires high resolution images of the whole surface of the coverslip with a hands-off workflow; FiberStudio, a software, which detects hybridization signals and analyzes data to generate results and reporting; FiberPrep, a DNA extraction kit that delivers purified DNA solutions for molecular combing; and accessories, such as custom treated glass carriers and disposable DNA reservoirs for use with the MCS, as well as sample cartridges for scanners. It also provides FiberProbes for BRCA that is a set of Genomic Morse Codes for the detection of mutations occurring in hereditary breast and ovarian cancer; and hereditary nonpolyposis colorectal cancer Genomic Morse Code sets, which allows the identification and characterization of various structural variations, including anomalies occurring in flanking regions of the MMR genes. In addition, the company offers combing services that allow customers to validate the planned gene editing events; detect incorrect events larger than 1kb, including incorrect deletions, insertions, or inversions; and quantify off-target/on-target ratios. It has a strategic alliance with Quest Diagnostics; and development agreement with La Timone Hospital; research and development agreement with the Institut Pasteur. Genomic Vision Société Anonyme was founded in 2004 and is headquartered in Bagneux, France.
Aziende con ebitda margin simili a Génomic Vision SA
- Golden Valley Mines ha EBITDA margin di -343.06%
- Golden Valley Mines ha EBITDA margin di -343.06%
- Endexx ha EBITDA margin di -342.80%
- Verde Bio ha EBITDA margin di -342.66%
- Keyne Ltd ha EBITDA margin di -342.52%
- Newfield Resources ha EBITDA margin di -342.47%
- Génomic Vision SA ha EBITDA margin di -342.13%
- Remark Inc ha EBITDA margin di -341.55%
- Versus Systems ha EBITDA margin di -341.28%
- Kernex Microsystems (India) ha EBITDA margin di -340.98%
- SQI Diagnostics ha EBITDA margin di -339.87%
- SQZ Biotechnologies Co ha EBITDA margin di -339.57%
- SugarBud Craft Growers ha EBITDA margin di -339.05%